US 11,702,417 B2
Compounds for improving mRNA splicing
Susan A. Slaugenhaupt, Hingham, MA (US); Graham Johnson, Sanbornton, NH (US); William D. Paquette, Amsterdam, NY (US); Wei Zhang, Sharon, MA (US); and Juan Marugan, Gaithersburg, MD (US)
Assigned to The General Hospital Corporation, Boston, MA (US); and The United States Of America, as represented by the secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The General Hospital Corporation, Boston, MA (US); and The United States of America, as Represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on May 18, 2020, as Appl. No. 16/877,254.
Application 16/877,254 is a continuation of application No. 15/543,826, granted, now 10,676,475, previously published as PCT/US2016/013553, filed on Jan. 15, 2016.
Claims priority of provisional application 62/180,380, filed on Jun. 16, 2015.
Claims priority of provisional application 62/104,547, filed on Jan. 16, 2015.
Prior Publication US 2020/0283441 A1, Sep. 10, 2020
Int. Cl. C07D 473/34 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01); C07D 513/04 (2006.01); C07D 473/16 (2006.01); A61P 25/28 (2006.01)
CPC C07D 473/34 (2013.01) [A61P 25/28 (2018.01); C07D 405/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 473/16 (2013.01); C07D 487/04 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01)] 13 Claims
 
1. A compound of Formula (Ic):

OG Complex Work Unit Chemistry
or a pharmaceutical acceptable salt thereof, wherein:
L is unsubstituted ethylene;
R1 is selected from the group consisting of:

OG Complex Work Unit Chemistry
each R1A is independently selected from the group consisting of chloro, bromo, CN, and C1-6 haloalkyl; and
R3, R4, R5, and R6 are each H.